KE / Domain	AOP entity (KE/KER)	Input (manipulation / sample)	Method / Assay (SOP notes)	Output / Measurement	Interpretation / Context fields to capture	Exemplar peer-reviewed manuscripts	Protocol / SOP notes (attach)	S&T considerations (ontology / mapping)
Mucociliary clearance (decreased)	KE: MCC, decreased (Event 10); downstream of CBF↓ and mucin changes; organ-level function	Primary human airway epithelial cells at ALI with established mucociliary phenotype; ex vivo tissue preparations	Fluorescence microscopy for mucus transport measurement. Fluorescent particles or labeled mucus applied to airway surface. Time-lapse imaging to track particle movement. Calculation of mucus transport rate (velocity in mm/min or µm/s). Assessment of transport directionality and uniformity. Temperature and humidity control during imaging.	Mucus transport rate (mm/min or µm/s); Transport directionality; Percentage of surface with active transport; Particle tracking trajectories	Cell type and donor; days at ALI; differentiation quality (% ciliated cells, CBF); fluorescent tracer type and size; imaging interval; temperature; humidity; microscope type; field of view; analysis method (manual tracking vs automated); replicate number	Roomans GM, Kozlova I, Nilsson H, Vanthanouvong V, Button B, and Tarran R. (2004). Measurements of airway surface liquid height and mucus transport by fluorescence microscopy, and of ion composition by X-ray microanalysis. J Cyst Fibros. 3 Suppl 2:135-9.	Include particle/tracer preparation, application method, imaging protocol (interval, duration), environmental control (temperature, humidity), particle tracking and velocity calculation, quality control for active vs passive movement	Biolink: MeasurementProcess; OBI: fluorescence microscopy, particle tracking; Mapping: KE MCC decrease (Event 10); Metadata: units (mm/min), environmental conditions; Functional readout of ciliary activity
Mucociliary clearance — μOCT	KE: MCC, decreased (Event 10); non-contact real-time assessment of mucociliary transport	Primary HAEC at ALI or ex vivo airway tissue; μOCT system (~1-2 µm axial resolution)	Micro-Optical Coherence Tomography (μOCT) for real-time mucociliary transport measurement. Non-contact cross-sectional imaging. Tracks endogenous mucus movement without added particles. Simultaneous measurement of MCT rate, CBF, ASL depth, and tissue microstructure. Depth-resolved analysis of mucus layer dynamics.	Mucociliary transport rate (mm/min); CBF (Hz); ASL depth (µm); Mucus layer thickness; Periciliary layer depth; Integrated functional assessment	Tissue type (cultured vs ex vivo); donor characteristics; days at ALI; μOCT system specifications (axial/lateral resolution, frame rate); imaging depth; calibration method; analysis algorithm for MCT extraction; temperature; replicate imaging fields	Liu L, Chu KK, Houser GH, Diephuis BJ, Li Y, Wilsterman EJ, et al. (2013). Method for quantitative study of airway functional microanatomy using micro-optical coherence tomography. PLoS One. 8(1):e54473.	Provide μOCT system configuration, imaging parameters, calibration with phantom, MCT analysis algorithm (motion tracking in depth-resolved images), quality control for motion artifacts, correlation of MCT with CBF and ASL measurements	Biolink: MeasurementProcess; OBI: optical coherence tomography assay; Mapping: KE MCC decrease (Event 10); Non-contact advantage; Multi-parameter simultaneous acquisition; Depth-resolved functional imaging
Mucociliary clearance — intranasal μOCT (clinical)	KE: MCC, decreased (Event 10); in vivo clinical assessment of mucociliary function	In vivo intranasal imaging in human subjects; ex vivo nasal tissue; μOCT probe for clinical use	Intranasal micro-Optical Coherence Tomography (μOCT). Minimally invasive in vivo imaging. Real-time measurement of mucociliary transport rate along with CBF and ASL properties. Non-contact optical imaging. Applicable to cystic fibrosis and other mucociliary disorders. Repeated measurements for longitudinal monitoring or treatment response.	Mucociliary transport rate (mm/min); CBF (Hz); ASL and PCL depths (µm); In vivo functional assessment; Comparison between healthy and disease states; Treatment response monitoring	Subject characteristics (age, disease state); anatomical site (nasal region); environmental conditions; probe positioning and stabilization; motion artifact correction; imaging duration; analysis software version; inter-subject and intra-subject variability; safety monitoring	Leung HM, Birket SE, Hyun C, Ford TN, Cui D, Solomon GM, et al. (2019). Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies. Sci Transl Med. 11(504).	Include patient preparation, probe handling and positioning, imaging protocol, motion correction algorithms, MCT extraction from in vivo data, quality assessment, safety considerations, regulatory compliance, correlation with clinical outcomes	Biolink: ClinicalMeasurement; OBI: optical coherence tomography; Mapping: KE MCC decrease in clinical context; In vivo functional biomarker; CF and mucociliary disorder assessment; Treatment monitoring
Mucociliary clearance in ALI cultures	KE: MCC, decreased (Event 10); in vitro model characterization and validation	Primary human tracheobronchial epithelial cells at ALI; characterization of mucociliary phenotype	Establishment and validation of ALI cultures for MCC studies. Assessment of differentiation markers (ciliated cells, goblet cells, mucin production). Functional MCC measurement using particle tracking. Correlation of MCC with cilia coverage, CBF, and mucin secretion. Model validation for pharmacological or genetic interventions.	MCC rate (µm/s or mm/min); Ciliated cell percentage; Goblet cell percentage; Mucin secretion rate; Correlation of MCC with cellular and molecular parameters; Model reproducibility metrics	Cell source and donor characteristics; culture medium formulation; days at ALI; differentiation quality control (transepithelial electrical resistance, histology); MCC measurement protocol; correlation analysis methods; inter-donor variability; passage effects	Hill DB, Button B, et al. (2012). [Establishment of ALI cultures for mucin and MCC studies].	Document ALI culture protocol, differentiation quality control criteria, MCC measurement method, cellular and molecular characterization assays, validation studies, acceptance criteria for model use	Biolink: MeasurementProcess; OBI: cell culture model, functional assay; Mapping: KE MCC decrease; In vitro model; Validation for drug screening and mechanistic studies; Correlation with in vivo function
Mucociliary clearance — porcine airway model	KE: MCC, decreased (Event 10); large animal model for translational MCC studies	Primary ciliated porcine airway epithelial cells at ALI; ex vivo porcine trachea preparations	Development of porcine airway epithelial ALI model. Characterization of mucociliary phenotype (ciliation, mucin production, CBF, MCC). Comparison to human airway models. Application to mucosal drug delivery studies. Functional MCC measurement and modulation by therapeutic agents.	MCC rate in porcine model; CBF; Ciliated cell coverage; Mucin production; Model-to-model comparison (porcine vs human); Drug delivery and MCC modulation	Porcine tissue source; cell isolation and culture protocol; ALI conditions; species-specific differentiation characteristics; MCC measurement method; comparison metrics to human; drug formulation and delivery approach; replicate number	Martin et al. (2025). Development and Characterization of a Primary Ciliated Porcine Airway Model for the Evaluation of In Vitro Mucociliary Clearance and Mucosal Drug Delivery.	Include porcine cell isolation protocol, ALI culture conditions, phenotypic characterization methods, MCC assay, comparison to human model, drug delivery protocols, validation of translational relevance	Biolink: MeasurementProcess; OBI: animal model, functional assay; Mapping: KE MCC; Translational model; Preclinical drug testing; Species comparison; Mucosal delivery assessment
Mucociliary clearance of bacterial biofilms	KE: MCC, decreased (Event 10); relationship to bacterial infection clearance	ALI airway cultures with Pseudomonas aeruginosa biofilms; combination treatments to enhance MCC and bacterial clearance	MCC measurement in the context of bacterial biofilm challenge. Biofilm formation on airway cultures. Treatment with mucolytics, CFTR modulators, or other agents. Assessment of MCC rate and biofilm clearance. Bacterial quantification (CFU counts). Correlation of MCC restoration with pathogen clearance.	MCC rate with and without biofilm; Biofilm clearance rate; Bacterial load (CFU); Treatment effects on MCC and bacterial clearance; Correlation between MCC restoration and pathogen reduction	Bacterial strain and culture conditions; biofilm formation protocol; treatment agents and concentrations; MCC measurement timing; bacterial quantification methods; culture viability; replicate number	Rouillard et al. [Combination treatment to improve mucociliary transport of Pseudomonas aeruginosa biofilms].	Document biofilm formation protocol, treatment administration, MCC measurement with biofilm present, bacterial quantification (CFU assay), correlation analysis, controls (no biofilm, no treatment)	Biolink: MeasurementProcess; OBI: functional assay, microbiological assay; Mapping: KE MCC decrease, infection context; CF therapeutic relevance; Host-pathogen interaction; Clearance mechanism
Mucociliary transport and ciliary orientation	KE: MCC, decreased (Event 10); role of ciliary orientation/polarity in directional transport	Patterned substrates to control ciliary orientation; ALI cultures with defined ciliary alignment; assessment of MCC directionality	Matrix patterning to induce ciliary orientation. Assessment of ciliary beat direction and coordination. Measurement of MCC velocity and directionality on patterned vs non-patterned surfaces. High-speed video microscopy for CBF and beat pattern. Quantification of transport efficiency as function of ciliary alignment.	MCC rate; MCC directionality (vector analysis); Ciliary orientation distribution; CBF; Correlation between ciliary alignment and transport efficiency	Substrate patterning method; pattern dimensions; ALI culture protocol on patterned substrates; ciliary orientation quantification method; MCC measurement and vector analysis; CBF assessment; replicate fields and cultures	Sears et al. [Induction of ciliary orientation by matrix patterning and characterization of mucociliary transport].	Include substrate patterning protocol, cell seeding and differentiation on patterned surfaces, ciliary orientation imaging and analysis, MCC vector field measurement, correlation of orientation and transport efficiency	Biolink: MeasurementProcess; OBI: functional assay, high-content imaging; Mapping: KE MCC, ciliary polarity; Mechanistic understanding; Engineered model; Directional transport control
Mucociliary clearance and viral pathogen spread	KE: MCC, decreased (Event 10); role in SARS-CoV-2 spread along airway epithelium	ALI airway cultures infected with SARS-CoV-2; live imaging of viral spread and MCC	Live imaging of airway epithelium during viral infection. Real-time tracking of viral spread (fluorescent reporter virus). Simultaneous measurement of MCC. Assessment of how MCC modulates viral dissemination. Pharmacological or genetic modulation of MCC and impact on infection spread.	Viral spread rate (mm/hour); MCC rate; Correlation between MCC and viral dissemination; Effect of MCC modulators on infection spread; Spatial patterns of infection relative to MCC	Viral strain and reporter system; infection protocol (MOI, duration); live imaging system and conditions; MCC measurement during infection; viral quantification (fluorescence, qPCR, plaque assay); MCC modulator treatments; biosafety protocols; replicate experiments	Becker et al. (2024). Live imaging of airway epithelium reveals that mucociliary clearance modulates SARS-CoV-2 spread.	Document viral infection protocol under BSL-3, live imaging setup, MCC measurement methods during infection, viral spread quantification, treatment protocols, biosafety considerations, data analysis for spatiotemporal dynamics	Biolink: MeasurementProcess; OBI: live cell imaging, viral infection assay; Mapping: KE MCC decrease, viral infection context; Host defense mechanism; COVID-19 relevance; MCC as antiviral barrier
